Drugs Made In America Acquisition Corp. has announced a delay in filing its quarterly financial report, Form 10-Q, for the period ending March 31, 2025. The notification of late filing was signed by CEO Lynn Stockwell on May 15, 2025. The company cited reasons that could not be resolved without unreasonable effort or expense and expects to file the report within five calendar days following the due date.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made In America Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-044303), on May 15, 2025, and is solely responsible for the information contained therein.